(Q45370218)

English

An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice

scientific article published on 24 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

0 references

Herpes simplex virus type 1

1 reference

based on heuristic

inferred from title

author name string

Kai Hu

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Jun Dou

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Fangliu Yu

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Xiangfeng He

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Xianwen Yuan

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Yaqing Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Chunsheng Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Ning Gu

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

language of work or name

0 references

publication date

24 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1455-1462

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Modalities to decrease stromal herpes simplex keratitis reactivation rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Genetic engineering of a modified herpes simplex virus 1 vaccine vector.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with beta2-adrenergic agonist

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

DNA vaccines against mycobacterial diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

DNA nanoparticles and development of DNA delivery vehicles for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Impact of timing strategy of LIGHT, a new TNF superfamily on immune platform induced by HSV-1 gB DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing mycobacterial antigen 85A and interleukin-21 and Bacillus Galmette-Guérin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Potential of nanocarriers in genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Nanoparticles as protein and gene carriers to mucosal surfaces.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Use of nanocarriers for transdermal vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Maghemite nanoparticles and their protamine derivatives: cellular internalization and effects on cell-cycle progress

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Cellular response to gene expression profiles of different hepatitis C virus core proteins in the Huh-7 cell line with microarray analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Effect of hepatitis C virus core shadow protein expressed in human hepatoma cell line on human gene expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Mycobacterium tuberculosis (Mtb) isocitrate dehydrogenases show strong B cell response and distinguish vaccinated controls from TB patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Antibody response to herpes simplex virus glycoprotein D: effects of acyclovir and relation to recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Viral immune evasion due to persistence of activated T cells without effector function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

IL-21 is required to control chronic viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

The ocular humoral immune response in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

The role of secretory antibodies in infection immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.031

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.12.031

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45370218&oldid=2075923608"